This site is intended for healthcare professionals
Drug news

Phase III data shows faster-acting insulin aspart reduces HbA1c in type 1 diabetes versus NovoRapid (insulin aspart) - Novo Nordisk

Read time: 1 mins
Last updated:15th Jun 2016
Published:15th Jun 2016
Source: Pharmawand

New phase IIIa findings showed that faster-acting insulin aspart, from Novo Nordisk, demonstrated a statistically significant reduction in HbA1c in type 1 diabetes, compared with NovoRapid (insulin aspart), a comparable HbA1c reduction in type 2 diabetes versus NovoRapid and improved post-meal or postprandial glucose (PPG) control in type 1 and type 2 diabetes. In onset 1, after 26 weeks of randomized therapy, faster-acting insulin aspart showed statistically significantly greater HbA1c reduction versus NovoRapid in adults with type 1 diabetes when dosed at mealtime. Faster-acting insulin aspart also showed comparable HbA1c reduction when dosed 20 minutes after starting a meal, compared with NovoRapid dosed at mealtime.

Trial results for onset 1 also showed superior reduction in two-hour PPG increment -0.67 mmol/L) versus NovoRapid. The change in one-hour PPG increment, a secondary supportive endpoint, was also reduced (-1.18 mmol/L). In onset 2, faster-acting insulin aspart demonstrated non-inferiority in HbA1c reduction compared with NovoRapid in adults with type 2 diabetes. Trial results could not confirm a statistically significant reduction in two-hour PPG increment ( -0.36 mmol/L). However, a statistically significant reduction in one-hour PPG increment was shown with faster-acting insulin aspart (-0.59 mmol/L) which was a secondary supportive endpoint. Results from the onset 1 and onset 2 treat-to-target trials comparing faster-acting insulin aspart with NovoRapid were presented at the 76th annual Scientific Sessions of the American Diabetes Association.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.